Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
Shuzhen Bai(Peking University), Linong Ji(Peking University), Suiyuan Hu(Peking University), Ruoyang Jiao(Peking University), Wenjia Yang(Peking University), Chu Lin(Peking University), Fang Lv(Liaoning Normal University), Xingyun Zhu(Peking University), Xiaoling Cai(Peking University)
Cited by 1
Related Papers
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
|Diabetologia|2020|373
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
|Nature Medicine|2024|152
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128